Cleerly

A new standard of care for heart disease.

Visit Website →

Overview

Cleerly offers a new approach to evaluating heart disease by using AI to analyze coronary CT angiograms (CCTA). Instead of just identifying blockages, Cleerly's platform quantifies and characterizes plaque, assessing a patient's overall risk of a heart attack to guide personalized, preventative treatment.

✨ Key Features

  • AI-powered plaque quantification and characterization
  • Stenosis measurement
  • Personalized risk assessment for heart attack
  • Longitudinal tracking of plaque progression
  • Cloud-based platform with structured reports

🎯 Key Differentiators

  • Focuses on plaque characterization and quantification, not just stenosis
  • Provides a more comprehensive view of disease activity
  • Aims to shift cardiology from a focus on stenosis to a focus on atherosclerosis

Unique Value: Provides a precise, non-invasive measurement of a patient's actual heart disease (plaque burden), enabling a more accurate prediction of heart attack risk and personalized care.

🎯 Use Cases (3)

Early detection and risk stratification of coronary artery disease Personalized treatment planning for heart disease Monitoring disease progression and response to therapy

✅ Best For

  • Quantification of atherosclerotic plaque from CCTA.

💡 Check With Vendor

Verify these considerations match your specific requirements:

  • Functional assessment of blood flow (FFR)

🏆 Alternatives

HeartFlow Traditional CCTA reading Calcium scoring

Goes beyond simply identifying blockages to characterize the type and amount of plaque, which is a better predictor of future cardiac events.

💻 Platforms

Web API

🔌 Integrations

PACS systems

🛟 Support Options

  • ✓ Email Support
  • ✓ Phone Support
  • ✓ Dedicated Support (Enterprise tier)

🔒 Compliance & Security

✓ SOC 2 ✓ HIPAA ✓ BAA Available ✓ GDPR ✓ ISO 27001 ✓ SSO ✓ FDA Cleared

💰 Pricing

Contact for pricing
Visit Cleerly Website →